for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Veracyte Inc

VCYT.OQ

Latest Trade

25.51USD

Change

-0.99(-3.74%)

Volume

48,856

Today's Range

25.49

 - 

26.55

52 Week Range

8.78

 - 

31.16

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
26.50
Open
26.46
Volume
48,856
3M AVG Volume
13.41
Today's High
26.55
Today's Low
25.49
52 Week High
31.16
52 Week Low
8.78
Shares Out (MIL)
48.45
Market Cap (MIL)
1,283.81
Forward P/E
-109.64
Dividend (Yield %)
--

Latest Developments

More

Veracyte Q2 Loss Per Share $0.05

Veracyte Appoints Keith Kennedy To Serve As Chief Operating Officer

Veracyte Announces Pricing Of Public Offering Of 5,500,000 Shares Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Veracyte Inc

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

Industry

Healthcare Facilities

Contact Info

6000 Shoreline Ct Ste 300

+1.650.2436300

https://www.veracyte.com/

Executive Leadership

Bonnie H. Anderson

Chairman of the Board, Chief Executive Officer

Keith S. Kennedy

Chief Financial Officer, Chief Operating Officer

Mark Ho

Principal Accounting Officer

Giulia C. Kennedy

Chief Scientific Officer, Chief Medical Officer

John L. Bishop

Lead Independent Director

Key Stats

1.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-1.090

2017

-0.910

2018

-0.620

2019(E)

-0.242
Price To Earnings (TTM)
--
Price To Sales (TTM)
11.79
Price To Book (MRQ)
5.70
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.33
LT Debt To Equity (MRQ)
0.26
Return on Investment (TTM)
-8.21
Return on Equity (TTM)
-7.54

Latest News

BRIEF-Veracyte Files For Mixed Shelf Of Up To $125 Million

* VERACYTE INC FILES FOR MIXED SHELF OF UP TO $125 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2jlv3GH) Further company coverage:

BRIEF-Veracyte Q1 Loss Per Share $0.27

* Q1 EARNINGS PER SHARE VIEW $-0.25 -- THOMSON REUTERS I/B/E/S

BRIEF-Veracyte Announces Precision Medicine Collaboration With Loxo Oncology

* VERACYTE ANNOUNCES PRECISION MEDICINE COLLABORATION WITH LOXO ONCOLOGY

BRIEF-Veracyte Inc Q4 Net Loss Per Common Share $0.24

* VERACYTE ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK

BRIEF-Veracyte Announces Strategic Realignment And New Appointments To Advance Commercial Growth

* VERACYTE ANNOUNCES STRATEGIC REALIGNMENT AND NEW APPOINTMENTS TO ADVANCE COMMERCIAL GROWTH

BRIEF-Veracyte posts Q3 loss per share $0.21

* Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S

BRIEF-Veracyte announces release of 2018 preliminary reimbursement rate for Afirma Genomic Classifier under PAMA

* Veracyte Inc - reimbursement rate for Afirma Genomic Classifier is expected to increase from $3,220 to $3,600 for calendar year 2018

BRIEF-Veracyte announces pivotal clinical validation data

* Veracyte announces pivotal clinical validation data for next-generation afirma test to help more patients avoid unnecessary surgery in thyroid cancer diagnosis

BRIEF-Veracyte reports qtrly loss per share $0.14

* Veracyte announces fourth quarter and full-year 2016 financial results, provides 2017 financial outlook

BRIEF-Veracyte names Christopher Hall as COO

* Veracyte - Christopher Hall has been named president and chief operating officer and John W. Hanna has been promoted to chief commercial officer

BRIEF-Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis

* Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis through agreement with quest diagnostics

BRIEF-Broadfin Capital Llc reports 5.8 pct passive stake in Veracyte Inc

* Broadfin Capital Llc reports 5.8 percent passive stake in Veracyte Inc as of Nov 2 - SEC Filing Source text - http://bit.ly/2ewciyN

BRIEF-Veracyte announces third quarter 2016 financial results

* Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Veracyte prices public offering of 5 mln shares of common stock

* Pricing of an underwritten public offering of 5 million shares of its common stock at a public offering price of $6.00 per share

BRIEF-Veracyte releases statement on CMS's final 2017 gapfill rate for afirma gene expression classifier

* Veracyte releases statement on cms's final 2017 gapfill rate for afirma gene expression classifier

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up